Renaissance Capital logo

EVO News

Renaissance Capital’s November IPO Market Update

RIVN

During November, 34 IPOs raised $17.6 billion, the IPO market's biggest November since 1999. Blank check companies continued to gain momentum, as 60 SPACs raised $11.1 billion. The most active sector was technology, which accounted for 11 of the month's IPOs and included a mix of consumer engagement software, cloud storage, and crypto mining. Familiar consumer brands like Hertz,...read more

US IPO Weekly Recap: Allbirds spreads its wings and soars 93% in a 12 IPO week

BIRD

November kicked off with a 12 IPO week and shoe brand Allbirds (BIRD) was at the front of the flock, posting a first-day pop of 93%. 23 SPACs also went public. New issuers continued to join the pipeline, with five IPOs and 13 SPACs submitting initial filings. Two issuers postponed this past week: Russian car-sharing firm Delimobil (DMOB) and...read more

Germany-listed drug discovery company Evotec prices downsized US IPO at $21.75

EVO

Evotec, which provides drug discovery solutions for the pharmaceutical industry, raised $435 million by offering 20 million ADSs at $21.75, below the as-converted last close of its shares on the Frankfurt Stock Exchange ($22.87). The company offered 2 million fewer ADSs than anticipated. The company calls itself an industry-leading drug discovery and development partner for the...read more

US IPO Week Ahead: Steady IPO deal flow set to continue with 13 IPOs slated for next week

EVO

Updated Monday, 11/1. The IPO market has seen double digit offerings for the past two weeks, and is scheduled to continue its streak, with 13 IPOs expected to raise $2.7 billion. Drug discovery company Evotec (EVO) plans to raise $576 million at a $9.2 billion market cap. The company aims to accelerate and improve the efficiency of the drug discovery...read more